Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 58

Results For "EY"

5017 News Found

Genethon and Ampersand team up to engineer next-gen gene therapy vectors with precision
Biotech | May 26, 2026

Genethon and Ampersand team up to engineer next-gen gene therapy vectors with precision

AAV vectors are widely used in gene therapy for their strong therapeutic potential


Datroway wins US nod in aggressive breast cancer subtype
Drug Approval | May 25, 2026

Datroway wins US nod in aggressive breast cancer subtype

Clearance marks major shift beyond chemotherapy


Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors
News | May 25, 2026

Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors

The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks


Anupam Rasayan to acquire 43.3%–48.2% equity stake in Bliss GVS Pharma
News | May 25, 2026

Anupam Rasayan to acquire 43.3%–48.2% equity stake in Bliss GVS Pharma

The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment


SMS Pharma posts 48% profit surge in FY26 as margins expand & portfolio shift drives growth
News | May 25, 2026

SMS Pharma posts 48% profit surge in FY26 as margins expand & portfolio shift drives growth

Revenue from operations climbed 13% to Rs. 886.87 crore


Akumentis Healthcare appoints Dharnendra Doshi as Senior Vice President
People | May 25, 2026

Akumentis Healthcare appoints Dharnendra Doshi as Senior Vice President

Veteran consumer health and FMCG strategist to lead preventive wellness and nutrition portfolio expansion through innovation and modern trade channels


EMA accepts filing for Teva and Medincell’s long-acting schizophrenia treatment candidate
News | May 25, 2026

EMA accepts filing for Teva and Medincell’s long-acting schizophrenia treatment candidate

If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings


Lilly brings heavy oncology firepower to ASCO with plenary data across cancers
R&D | May 25, 2026

Lilly brings heavy oncology firepower to ASCO with plenary data across cancers

The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy


Bristol Myers Squibb to unveil massive oncology data push at ASCO 2026
R&D | May 25, 2026

Bristol Myers Squibb to unveil massive oncology data push at ASCO 2026

The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”


AbbVie signals major oncology momentum at ASCO
R&D | May 25, 2026

AbbVie signals major oncology momentum at ASCO

With standout ADC and t-cell engager response data across hard-to-treat cancers